Grifols SA (GRF)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Mar 14, 2025

$10.19

P/E Ratio

40.72

Market Cap

$6.32B

Loading...
Description
Add to research
View more

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Metrics
Add to research
View more

Overview

  • HQBarcelona, CT
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerGRF
  • Price$10.190295+1.39%

Trading Information

  • Market cap$6.32B
  • Float42.79%
  • Average Daily Volume (1m)3,032,918
  • Average Daily Volume (3m)2,108,977
  • EPS$0.23

Company

  • Revenue$7.21B
  • Rev growth (1yr)9.41%
  • Net income$156.92M
  • Gross margin36.46%
  • EBITDA margin21.66%
  • EBITDA$1.56B
  • EV$17.17B
  • EV/Revenue2.38
  • P/E40.72
  • P/S0.89
  • P/B1.09
  • Debt/Equity156.39
Documents
Add to research
View more